Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.
Metrics to compare | 4889 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4889PeersSector | |
---|---|---|---|---|
P/E Ratio | 257.3x | 10.2x | −0.5x | |
PEG Ratio | 1.71 | 0.07 | 0.00 | |
Price/Book | 16.9x | 1.2x | 2.6x | |
Price / LTM Sales | 220.2x | 1.1x | 3.0x | |
Upside (Analyst Target) | - | 3.3% | 49.2% | |
Fair Value Upside | Unlock | 5.2% | 7.4% | Unlock |